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Introduction: Gliomas are the most common type of primary malignant brain tumors and are 
graded into I to IV according to their increasing malignancy. Classification of Grade III (anaplastic 
astrocytoma) and IV (glioblastoma multiforme) is important not only because of the difference in 
the survival time of patients but also because of the significant guidance provided for therapeutic 
decisions. 
Results: In this study, we conducted a predictive meta-analysis of multiple Affymetrix U133 
microarrays to identify a set of signature genes that can distinguish glioblastoma multiforme from 
anaplastic astrocytoma. Our classifier, which was based on the nearest shrunken centroids, contained 
229 genes and achieved an accuracy, sensitivity, specificity, and J index of 75%, 78.5%, 
74.1%, and 52.6%, respectively, using a dataset cross-validation procedure. Based on the identified 
gene signature, we found 13 pathways, most of which have been already linked in a number of 
sporadic studies to high-grade gliomas. 
Conclusion: The results of this study can be potentially used: (1) to shed light on the 
molecular mechanisms underlying the formation of malignant gliomas; and (2) to match malignant 
glioma individuals with treatment strategies based on their gene expression profiles. 
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